Drug-Eluting Stent

Biodegradable polymer sirolimus-eluting stent (Tivoli, Essen) vs. durable polymer SES (Firebird2, Microport) in patients with CAD.

Among patients who underwent PCI with a drug-eluting stent, switching from dual antiplatelet therapy to ticagrelor monotherapy at 3 months was similarly beneficial in men and women, according to new data from the TWILIGHT trial.

SES with biodegradable polymer (Orsiro, Biotronik) vs. EES with durable polymer (Xience Xpedition/Alpine, Abbott Vascular) for PCI in patients with STEMI.

A biodegradable polymer sirolimus-eluting stent remained superior to a durable polymer everolimus-eluting stent at 2 years, researchers reported.

Novel healing-targeted drug-eluting stent (HT-DES; BuMA Supreme, Sinomed) vs. durable polymer everolimus-eluting stents for PCI.

Boston Scientific announced it received FDA approval for its drug-eluting stent system designed to treat large, proximal vessels.

Among patients who underwent PCI with a sirolimus-eluting stent, short-term and long-term dual antiplatelet therapy conferred similar rates of target vessel failure, researchers reported.

An interim analysis of the SWEDEPAD trial, which was paused after a meta-analysis detected a mortality hazard associated with paclitaxel-coated devices, found no death risk from the devices in patients with peripheral artery disease.

Healio and Cardiology Today have aggregated the most-read news from the virtual VIVA 20.

Outcomes with 14 days of dual antiplatelet therapy after PCI with a nanocoated stent (Cobra PzF, CeloNova Biosciences) compared with 3- to 6-month DAPT after PCI with a drug-eluting stent.